Use of antisense oligonucleotides against CPLA2 in the treatment of cancer

Rachel Levy

Use of antisense oligonucleotides against CPLA2 in the treatment of cancer

Rachel Levy (Inventor)

Research output: Patent

Abstract

Inhibitors of cPLA2α expression are used in the preparation of pharmaceutical compositions for the inhibition of cancer cell proliferation and for the treatment of cancer; the inhibitors are selected from cPLA2α-specific ribozymes, RNA sequences usable for RNA-interference of the cPLA2α gene, and antisense oligonucleotides directed against cPLA2α.

Original language	English
Patent number	US8895523B2
State	Published - 25 Nov 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.researchgate.net/publication/302802420_Use_of_antisense_oligonucleotides_against_CPLA2_in_the_treatment_of_cancer

Cite this

@misc{846fc756d1de47ba8299264ed31de039,

title = "Use of antisense oligonucleotides against CPLA2 in the treatment of cancer",

abstract = "Inhibitors of cPLA2α expression are used in the preparation of pharmaceutical compositions for the inhibition of cancer cell proliferation and for the treatment of cancer; the inhibitors are selected from cPLA2α-specific ribozymes, RNA sequences usable for RNA-interference of the cPLA2α gene, and antisense oligonucleotides directed against cPLA2α.",

author = "Rachel Levy",

year = "2014",

month = nov,

day = "25",

language = "English",

type = "Patent",

note = "US8895523B2",

}

TY - PAT

T1 - Use of antisense oligonucleotides against CPLA2 in the treatment of cancer

AU - Levy, Rachel

PY - 2014/11/25

Y1 - 2014/11/25

N2 - Inhibitors of cPLA2α expression are used in the preparation of pharmaceutical compositions for the inhibition of cancer cell proliferation and for the treatment of cancer; the inhibitors are selected from cPLA2α-specific ribozymes, RNA sequences usable for RNA-interference of the cPLA2α gene, and antisense oligonucleotides directed against cPLA2α.

AB - Inhibitors of cPLA2α expression are used in the preparation of pharmaceutical compositions for the inhibition of cancer cell proliferation and for the treatment of cancer; the inhibitors are selected from cPLA2α-specific ribozymes, RNA sequences usable for RNA-interference of the cPLA2α gene, and antisense oligonucleotides directed against cPLA2α.

M3 - Patent

M1 - US8895523B2

ER -

Use of antisense oligonucleotides against CPLA2 in the treatment of cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this